What is William Blair’s Forecast for Bio-Techne Q4 Earnings?

Bio-Techne Co. (NASDAQ:TECH) – Equities research analysts at William Blair cut their Q4 2025 earnings estimates for Bio-Techne in a note issued to investors on Wednesday, February 5th. William Blair analyst M. Larew now anticipates that the biotechnology company will post earnings of $0.51 per share for the quarter, down from their prior forecast of $0.52. The consensus estimate for Bio-Techne’s current full-year earnings is $1.68 per share. William Blair also issued estimates for Bio-Techne’s Q1 2026 earnings at $0.44 EPS, Q2 2026 earnings at $0.45 EPS, Q3 2026 earnings at $0.56 EPS and Q4 2026 earnings at $0.61 EPS.

Bio-Techne (NASDAQ:TECH) last issued its quarterly earnings data on Wednesday, February 5th. The biotechnology company reported $0.35 earnings per share for the quarter, missing the consensus estimate of $0.38 by ($0.03). Bio-Techne had a return on equity of 12.73% and a net margin of 13.22%.

A number of other equities analysts have also recently commented on the stock. Royal Bank of Canada lifted their target price on shares of Bio-Techne from $79.00 to $80.00 and gave the company a “sector perform” rating in a report on Thursday, February 6th. Robert W. Baird lifted their target price on shares of Bio-Techne from $82.00 to $84.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. Scotiabank lifted their target price on shares of Bio-Techne from $88.00 to $90.00 and gave the company a “sector outperform” rating in a report on Thursday, February 6th. StockNews.com raised shares of Bio-Techne from a “hold” rating to a “buy” rating in a report on Tuesday, November 12th. Finally, KeyCorp lifted their target price on shares of Bio-Techne from $80.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday, February 6th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, Bio-Techne currently has an average rating of “Moderate Buy” and an average price target of $86.57.

Bio-Techne Stock Down 4.0 %

Shares of NASDAQ:TECH opened at $69.92 on Monday. The company has a market capitalization of $11.11 billion, a PE ratio of 70.63, a P/E/G ratio of 5.54 and a beta of 1.27. The company has a current ratio of 3.94, a quick ratio of 3.26 and a debt-to-equity ratio of 0.14. Bio-Techne has a twelve month low of $61.16 and a twelve month high of $85.57. The firm has a 50 day simple moving average of $74.44 and a 200-day simple moving average of $74.24.

Bio-Techne Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, February 28th. Shareholders of record on Monday, February 17th will be given a dividend of $0.08 per share. The ex-dividend date is Friday, February 14th. This represents a $0.32 annualized dividend and a dividend yield of 0.46%. Bio-Techne’s payout ratio is currently 32.32%.

Insiders Place Their Bets

In related news, CEO Kim Kelderman sold 13,392 shares of the business’s stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $77.29, for a total value of $1,035,067.68. Following the sale, the chief executive officer now directly owns 39,004 shares in the company, valued at $3,014,619.16. The trade was a 25.56 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 3.90% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TECH. Sanctuary Advisors LLC purchased a new position in Bio-Techne in the 2nd quarter valued at about $564,000. Czech National Bank lifted its holdings in Bio-Techne by 6.9% in the 3rd quarter. Czech National Bank now owns 32,101 shares of the biotechnology company’s stock valued at $2,566,000 after purchasing an additional 2,072 shares in the last quarter. Mather Group LLC. lifted its holdings in Bio-Techne by 51.5% in the 3rd quarter. Mather Group LLC. now owns 612 shares of the biotechnology company’s stock valued at $49,000 after purchasing an additional 208 shares in the last quarter. Livforsakringsbolaget Skandia Omsesidigt lifted its holdings in Bio-Techne by 674.2% in the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,378 shares of the biotechnology company’s stock valued at $110,000 after purchasing an additional 1,200 shares in the last quarter. Finally, Exchange Traded Concepts LLC purchased a new position in Bio-Techne in the 3rd quarter valued at about $185,000. 98.95% of the stock is currently owned by hedge funds and other institutional investors.

About Bio-Techne

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.